Privileged Scaffold Decoration for the Identification of the First Trisubstituted Triazine with Anti-SARS-CoV-2 Activity

Current therapy against severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) are based on the use of Remdesivir 1, Molnupiravir 2, and the recently identified Nirmatrelvir 3. Unfortunately, these three drugs showed some limitations regarding potency and possible drug–drug interactions....

Descripción completa

Detalles Bibliográficos
Autores principales: Cesarini, Silvia, Vicenti, Ilaria, Poggialini, Federica, Secchi, Massimiliano, Giammarino, Federica, Varasi, Ilenia, Lodola, Camilla, Zazzi, Maurizio, Dreassi, Elena, Maga, Giovanni, Botta, Lorenzo, Saladino, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782877/
https://www.ncbi.nlm.nih.gov/pubmed/36557962
http://dx.doi.org/10.3390/molecules27248829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9782877/
https://www.ncbi.nlm.nih.gov/pubmed/36557962
http://dx.doi.org/10.3390/molecules27248829

Ejemplares similares